Infliximab in therapy of inflammatory bowels diseases

Skrócona strona pozycji
dc.contributor.authorBar, Piotr
dc.contributor.authorGaliniak, Sabina
dc.contributor.authorBartusik-Aebisher, Dorota
dc.contributor.authorFilip, Rafał
dc.contributor.authorAebisher, David
dc.date.accessioned2019-04-15T08:57:43Z
dc.date.available2019-04-15T08:57:43Z
dc.date.issued2019
dc.descriptionDorota Bartusik-Aebisher acknowledges support from the National Center of Science NCN (New drug delivery systems-MRI study, Grant OPUS-13 number 2017/25/B/ST4/02481).pl_PL.UTF-8
dc.description.abstractIntroduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab. Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran). Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab. Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response.pl_PL.UTF-8
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 17, z. 1 (2019), s. 79–82pl_PL.UTF-8
dc.identifier.doi10.15584/ejcem.2019.1.13
dc.identifier.eissn2544-1361
dc.identifier.issn2544-2406
dc.identifier.urihttp://repozytorium.ur.edu.pl/handle/item/4527
dc.language.isoengpl_PL.UTF-8
dc.publisherWydawnictwo Uniwersytetu Rzeszowskiegopl_PL.UTF-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectinfliximabpl_PL.UTF-8
dc.subjectTNFαpl_PL.UTF-8
dc.subjectulcerative colitispl_PL.UTF-8
dc.titleInfliximab in therapy of inflammatory bowels diseasespl_PL.UTF-8
dc.typereviewpl_PL.UTF-8
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
13 bar-infliximab in therapy.pdf
Rozmiar:
111.79 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.22 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019)